Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3033 |
|
| Actual shortage: | 243 (8%) | |
| Anticipated shortage: | 15 (0%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2766 (91%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
32 (11%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2023-06-23 | 2023-06-29 | 196303 |
| APO-RIZATRIPTAN RPD | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2020-07-06 | 490 |
| APO-RIZATRIPTAN RPD | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2018-09-11 | 493 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-03-12 | 2017-03-31 | 725 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-04-24 | 2017-06-13 | 7716 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-05-02 | 2017-08-16 | 8710 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-05-02 | 2017-08-17 | 8713 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-06-28 | 2017-10-03 | 14223 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-06-28 | 2017-11-03 | 14227 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-08-08 | 2017-11-07 | 18560 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-08-29 | 2017-10-30 | 20623 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-08-29 | 2017-11-03 | 20626 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-11-07 | 2018-03-20 | 28440 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-11-28 | 2018-02-27 | 30960 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-11-28 | 2018-03-13 | 31031 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-11-28 | 2018-03-20 | 31034 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2019-02-13 | 2019-03-07 | 75629 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-04-18 | 2019-05-13 | 82019 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-12-18 | 2020-03-09 | 101517 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2021-04-30 | 2021-05-25 | 138355 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78141 | ||
| APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78144 | ||
| APO PREDNISONE TAB 1MG USP | 1MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1056 |
| APO PREDNISONE TAB 5MG | 5MG | TABLET | Discontinued | 2018-09-08 | 2018-12-28 | 60699 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Discontinued | 2018-09-08 | 2019-02-13 | 60837 |
| APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG 300MG | TABLET | Discontinued | 2022-12-12 | 2022-12-12 | 177953 |
| APO-ACEBUTOLOL | 400MG | TABLET | Discontinued | 2017-03-31 | 2018-02-05 | 4965 |
| APO-ACETAMINOPHEN CAPLETS EXTRA STRENGTH | 500MG | TABLET | Discontinued | 2018-09-07 | 2018-09-08 | 60157 |
| APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2018-09-07 | 2019-12-20 | 60163 |
| APO-ALENDRONATE | 5MG | TABLET | Discontinued | 2019-01-03 | 2019-12-21 | 71023 |
| APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2019-01-03 | 2019-12-20 | 71026 |
| APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83971 | ||
| APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83976 | ||
| APO-AMITRIPTYLINE | 10MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71348 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Discontinued | 2019-01-04 | 2019-02-13 | 71351 |
| APO-AMITRIPTYLINE | 50MG | TABLET | To be discontinued | 2019-01-04 | 2021-06-05 | 71354 |
| APO-AMOXI | 250MG | CAPSULE | Discontinued | 2018-09-07 | 2019-02-13 | 60171 |
| APO-AMOXI | 500MG | CAPSULE | Discontinued | 2018-09-07 | 2018-11-09 | 60174 |
| APO-AMOXI CLAV | Discontinued | 2019-05-17 | 2019-05-18 | 84392 | ||
| APO-AMOXI CLAV 125MG/31.25MG PER 5ML | 125MG 31.25MG | POWDER FOR SUSPENSION | Discontinued | 2017-03-31 | 2017-03-31 | 4903 |